CN102973520B - 一种含有二乙酰胺乙酸乙二胺化合物的药物组合物 - Google Patents
一种含有二乙酰胺乙酸乙二胺化合物的药物组合物 Download PDFInfo
- Publication number
- CN102973520B CN102973520B CN 201210303753 CN201210303753A CN102973520B CN 102973520 B CN102973520 B CN 102973520B CN 201210303753 CN201210303753 CN 201210303753 CN 201210303753 A CN201210303753 A CN 201210303753A CN 102973520 B CN102973520 B CN 102973520B
- Authority
- CN
- China
- Prior art keywords
- ethylenediamine
- trisodium citrate
- mannitol
- vitamin
- disodiumhydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 title abstract description 11
- -1 Diethylamide ethylenediamine compound Chemical class 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 title abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 28
- 239000001509 sodium citrate Substances 0.000 claims abstract description 22
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims abstract description 22
- 229940038773 trisodium citrate Drugs 0.000 claims abstract description 22
- 239000000872 buffer Substances 0.000 claims abstract description 20
- 238000002347 injection Methods 0.000 claims abstract description 17
- 239000007924 injection Substances 0.000 claims abstract description 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 16
- 229930195725 Mannitol Natural products 0.000 claims abstract description 16
- 239000000594 mannitol Substances 0.000 claims abstract description 16
- 235000010355 mannitol Nutrition 0.000 claims abstract description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 14
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 14
- 239000011718 vitamin C Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 28
- 150000001408 amides Chemical class 0.000 claims description 28
- 239000002526 disodium citrate Substances 0.000 claims description 20
- 235000019262 disodium citrate Nutrition 0.000 claims description 20
- 229940079896 disodium hydrogen citrate Drugs 0.000 claims description 20
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims description 20
- JHECKPXUCKQCSH-UHFFFAOYSA-J calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical compound O.[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-J 0.000 claims description 14
- 238000004090 dissolution Methods 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 5
- PRZPUYBFEJPNPF-UHFFFAOYSA-J tetrasodium 3-carboxy-3,5-dihydroxy-5-oxopentanoate 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Na+].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Na+].[Na+].[Na+].C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-] PRZPUYBFEJPNPF-UHFFFAOYSA-J 0.000 abstract 2
- AHFBKHFXNNGDHB-UHFFFAOYSA-N CCNCC.CC(O)=O.NCCN Chemical compound CCNCC.CC(O)=O.NCCN AHFBKHFXNNGDHB-UHFFFAOYSA-N 0.000 abstract 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 abstract 1
- YOFCJURFOOBAAW-UHFFFAOYSA-N ethane-1,2-diamine;n-ethylethanamine Chemical compound NCCN.CCNCC YOFCJURFOOBAAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000008176 lyophilized powder Substances 0.000 abstract 1
- 229940012017 ethylenediamine Drugs 0.000 description 23
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000012535 impurity Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 5
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- GKNAKQZZLBLSLI-UHFFFAOYSA-N 2-acetamidoacetic acid;ethane-1,2-diamine Chemical compound NCCN.CC(=O)NCC(O)=O.CC(=O)NCC(O)=O GKNAKQZZLBLSLI-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010038727 Respiratory tract haemorrhage Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210303753 CN102973520B (zh) | 2012-07-12 | 2012-08-22 | 一种含有二乙酰胺乙酸乙二胺化合物的药物组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210240308.4 | 2012-07-12 | ||
CN201210240308 | 2012-07-12 | ||
CN 201210303753 CN102973520B (zh) | 2012-07-12 | 2012-08-22 | 一种含有二乙酰胺乙酸乙二胺化合物的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102973520A CN102973520A (zh) | 2013-03-20 |
CN102973520B true CN102973520B (zh) | 2013-12-25 |
Family
ID=47848057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210303753 Active CN102973520B (zh) | 2012-07-12 | 2012-08-22 | 一种含有二乙酰胺乙酸乙二胺化合物的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102973520B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1541647A (zh) * | 2003-11-06 | 2004-11-03 | 武汉佑德医药科技有限公司 | 二乙酰氨乙酸乙二胺粉针制剂及其制备方法 |
CN102367229A (zh) * | 2011-08-19 | 2012-03-07 | 江西新先锋医药有限公司 | 一种二乙酰氨乙酸乙二胺化合物及其药物组合物 |
CN102488663A (zh) * | 2011-12-19 | 2012-06-13 | 王保明 | 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 |
-
2012
- 2012-08-22 CN CN 201210303753 patent/CN102973520B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1541647A (zh) * | 2003-11-06 | 2004-11-03 | 武汉佑德医药科技有限公司 | 二乙酰氨乙酸乙二胺粉针制剂及其制备方法 |
CN102367229A (zh) * | 2011-08-19 | 2012-03-07 | 江西新先锋医药有限公司 | 一种二乙酰氨乙酸乙二胺化合物及其药物组合物 |
CN102488663A (zh) * | 2011-12-19 | 2012-06-13 | 王保明 | 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
注射用二乙酰氨乙酸乙二胺的工艺筛选;谢建军等;《中南药学》;20050831;第3卷(第4期);全文 * |
谢建军等.注射用二乙酰氨乙酸乙二胺的工艺筛选.《中南药学》.2005,第3卷(第4期),全文. |
Also Published As
Publication number | Publication date |
---|---|
CN102973520A (zh) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103462911B (zh) | 一种冻干粉针剂的制备技术 | |
CN106176617A (zh) | 阿莫西林可溶性粉及其制备方法 | |
CN102038635A (zh) | 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法 | |
CN102525963B (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
CN102784382B (zh) | 一种阿加曲班药物组合物及其制备方法和应用 | |
CN106265536A (zh) | 硼替佐米药物组合物及其制备方法 | |
CN104414977A (zh) | 一种注射用青蒿琥酯和l-精氨酸组合物及其制备方法 | |
CN102138909B (zh) | 门冬酰胺酶冻干粉针剂及其制备方法以及门冬酰胺酶溶解液 | |
CN104013629B (zh) | 头孢哌酮钠他唑巴坦钠的复方药物组合物及其制备工艺 | |
CN102488663B (zh) | 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 | |
CN102973520B (zh) | 一种含有二乙酰胺乙酸乙二胺化合物的药物组合物 | |
CN104434803A (zh) | 一种注射用青蒿琥酯和l-赖氨酸组合物及其制备方法 | |
CN102367229B (zh) | 一种二乙酰氨乙酸乙二胺化合物及其药物组合物 | |
CN102988305B (zh) | 一种含有环磷腺苷葡胺化合物的药物组合物 | |
CN104800172A (zh) | 注射用卡络磺钠粉针剂和制法 | |
CN102988306B (zh) | 一种含有奥扎格雷钠化合物的药物组合物 | |
CN103520186B (zh) | 一种注射用脂溶性维生素的药物组合物及其制备方法 | |
CN102988304B (zh) | 一种含有盐酸赖氨酸化合物的药物组合物 | |
CN101152174B (zh) | 一种稳定的利福霉素钠注射液的处方及制备方法 | |
CN100467024C (zh) | 氯诺昔康注射用组合物及其制备方法 | |
CN102335136A (zh) | 一种供注射用美罗培南药物组合物及其制备方法 | |
CN103565747B (zh) | 一种埃索美拉唑药物组合物及其制备方法 | |
CN103040762B (zh) | 一种含有盐酸格拉司琼化合物的药物组合物 | |
CN101890015B (zh) | 一种哌拉西林钠他唑巴坦钠药物组合物脂质体注射剂 | |
CN102988954B (zh) | 一种含有胸腺五肽化合物的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LUO CHENG Free format text: FORMER OWNER: YAO YUN Effective date: 20140211 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 355114 NINGDE, FUJIAN PROVINCE TO: 364000 LONGYAN, FUJIAN PROVINCE |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140211 Address after: Room 601, building A, Shengshi Road, Renmin Road, Fujian, Longyan, 364000 Patentee after: Luo Cheng Address before: 355114 Fujian city of Ningde province Xiapu County Xia Hu Zhen Jin Fu Street No. 5 building 503 room Patentee before: Yao Yun |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130320 Assignee: China National Medicines Guorui Pharmaceutical Co., Ltd. Assignor: Luo Cheng Contract record no.: 2014990000118 Denomination of invention: Diethylamide ethylenediamine compound-containing drug composition Granted publication date: 20131225 License type: Common License Record date: 20140310 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: China National Medicines Guorui Pharmaceutical Co., Ltd. Assignor: Luo Cheng Contract record no.: 2014990000118 Date of cancellation: 20150319 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130320 Assignee: China National Medicines Guorui Pharmaceutical Co., Ltd. Assignor: Luo Cheng Contract record no.: 2015990000127 Denomination of invention: Diethylamide ethylenediamine compound-containing drug composition Granted publication date: 20131225 License type: Common License Record date: 20150325 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model |